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Introduction
A major contributor to the signiﬁ  cant recent decline in 
breast cancer mortality is the use of adjuvant endocrine 
therapy. However, the overall eﬃ   cacy  of  tamoxifen, 
aroma  tase inhibitors, and the pure antiestrogen, fulves-
trant, is limited by de novo and acquired resistance. Th  e 
article by Hutcheson and colleagues [1] in the previous 
issue of Breast Cancer Research further develops our 
understanding of the role of the ErbB family in endocrine 
resistance by providing new insights into the roles of 
ErbB-3 and -4 in modulating sensitivity to fulvestrant.
Since endocrine resistance may compromise the 
eﬀ  ective treatment and potential cure of up to 25% of all 
breast cancers, deﬁ   ning the mechanisms of endocrine 
resistance has been a major research focus. Th   is body of 
research identiﬁ  es a wide range of biological mechanisms 
that can confer endocrine resistance in vitro. Th  ese 
include the following: loss of estrogen receptor-alpha 
(ERα) expression and expression of truncated isoforms of 
ERα and ERβ; post-translational modiﬁ  cation, particu-
larly phosphorylation of ERα; increased activity of other 
transcription factors, including AP1 and c-Myc; deregu-
la  tion of ER coactivators; and increased receptor tyrosine 
kinase signaling with resultant activation of the ERK and 
PI3K pathways and deregulation of the cell cycle, cell 
survival, and apoptotic machinery [2]. Although the 
direct relevance of these in vitro mechanisms to endo-
crine resistance in the clinic is far from clear, data 
accumulated in recent years provide strong evidence for a 
direct role for ErbB-2.
Since the initial observation that increased levels of 
both the epidermal growth factor receptor (EGFR/
ErbB-1) and ErbB-2 activate an autocrine growth-stimu-
latory pathway in tamoxifen-resistant MCF-7 cells [3], a 
number of laboratories have replicated and extended 
these ﬁ  ndings. Th  us, upregulation of ErbB-1 and -2 are 
common features of endocrine-resistant breast cancer 
cells, overexpression of these receptors confers insensi-
tivity to endocrine agents in xenograft models and in 
patients whose tumors overexpress these receptors, and 
these eﬀ  ects can be attenuated by therapies that target 
ErbB receptors in combination with tamoxifen (see [1] 
for references). Th   e article by Hutche  son and colleagues 
[1] extends these concepts to the other two members of 
the ErbB family.
Potential role of ErbB-3/4
Like EGFR and ErbB-2, ErbB-3 and -4 are transcrip-
tionally repressed by estrogen [4], and there is evidence 
of coregulation of the ER and ErbB pathways [5], the loss 
of which, in the case of ErbB-2, contributes to endocrine 
resistance [6]. ErbB-3 and -4 can form homodimers, but 
whereas ErbB-4 homodimers are active, ErbB-3 has im-
paired kinase activity and is active only when dimerized 
with another family member [7]. Whereas EGFR is 
activated by EGF and related growth factors, ErbB-3 and 
-4 are receptors for the neuregulins (NRGs) [7]. In breast 
cancer, the most important ligand appears to be heregulin 
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© 2011 BioMed Central Ltdβ (NRG2), which, when administered to MCF-7 cells, 
induces a hormone-independent phenotype [8]. Although 
the evidence for a role for the heregulins in endocrine 
resistance implies a role for ErbB-3 and -4, the mecha-
nisms are not well deﬁ  ned.
Hutcheson and colleagues [1] addressed this issue by 
exposing four ER+ breast cancer cell lines to fulvestrant 
for 7 days. Although the responses as measured by a 
spec  trum of cell proliferation and cell signaling endpoints 
showed some heterogeneity, a number of deﬁ  nitive 
conclusions were drawn. In support of earlier observa-
tions, fulvestrant treatment reduced ERα protein and ER-
mediated gene expression (progesterone receptor mRNA 
and cyclin D1 protein) and cell proliferation (cell number 
and Ki67 staining) in all four cell lines. Th   is was accom-
panied by increased ErbB-3 (MCF-7, T47D) and -4 
(BT474, MDAMB361) protein levels (but not mRNA 
levels) and enhanced basal phosphorylation of both 
recep  tors and ERK1/2.
Administration of HRGβ1 alone induced the expected 
activation of ErbB-3 and -4, ERK1/2, and AKT, although 
the eﬀ  ects on proliferation were varied. However, in the 
presence of fulvestrant, all four cell lines demonstrated 
enhanced sensitivity to HRGβ1 as measured by ErbB 
receptor, ERK1/2, and AKT phosphoryation; recovery of 
cyclin D1 expression; and enhanced proliferation. 
Notwith stand ing  some  diﬀ  erential eﬀ  ects in the four cell 
lines, the data are strongly supportive of the authors’ 
conclusions that antihormones, while inducing potent 
growth-inhibitory activity in ER+ breast cancer cells, 
simultaneously induce and activate growth factor 
pathways that override the initial response and render 
the cells refractory to the inhibitory eﬀ  ects of fulvestrant.
Th   ese data are in good agreement with those of recent 
publications demonstrating that ErbB-3 is activated in 
tamoxifen-resistant [9] and fulvestrant-resistant [10] cells 
and that downregulation of ErbB-3 abrogates ErbB-2-
mediated tamoxifen resistance [9]. However, further 
work is needed to clarify the role of ErbB-4. Lykkesfeldt 
and colleagues [10] reported that this receptor is down-
regulated in fulvestrant-resistant MCF-7 cells, whereas 
others report upregulation in tamoxifen-resistant cells 
[11]. Th   ere are also inconsistent data on whether ErbB-4 
is estrogen-induced [12] or antiestrogen-induced [1] and 
whether this is mediated at the transcriptional or post-
transcriptional level.
Conclusions
Th   e study by Hutcheson and colleagues raises a number 
of important issues relating to further deﬁ  ning 
mechanisms of endocrine resistance and to the identi  ﬁ  -
cation of new therapeutic targets for future clinical 
testing. Th   eir hypothesis-testing approach identiﬁ  es two 
new targets but raises the question ‘How many targets 
are there?’ Given that ErbB-3 and -4 were upregulated at 
the protein level and not the mRNA level, a more global 
set of approaches to kinase and kinase substrate 
identiﬁ   cation [13] in endocrine-resistant disease may 
yield a broader range of targets. Equally important is the 
translation of these data to the clinic. Although 
combinations of antihormones and growth factor inhibi-
tors have shown great promise in experimental systems, 
they have, to date, been relatively disappointing in the 
clinic [14]. Th  us,  deﬁ  ning new mechanisms, new targets, 
and companion biomarkers that aid in patient selection 
remains a high priority. Given the current data [1], broad-
spectrum ErbB inhibitors and antibodies that inhibit 
ErbB heterodimerization [15] warrant further detailed 
evaluation in endocrine-resistant disease.
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